Aktienanalyse zu Pliant Therapeutics Inc (PLRX)PLRXPliant Therapeutics Inc

Pliant Therapeutics, Inc. is a late-stage biotechnology company, which is focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Pliant Therapeutics Inc is currently trading at $0.8392, which is very close to its 52-week low of $0.83. The RSI is at 30.592, indicating that the stock is oversold, but the company continues to report significant losses, with a net income loss of $23.577 million in Q4 2025. While there are some positive developments in their oncology focus, the overall financial performance and recent stock decline suggest caution. The main risk is the company's ongoing negative earnings, with an EPS of -0.36 reported last quarter, which raises concerns about its profitability moving forward.